Clinical trials: AE COPD
COPD, OSA
Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD) Patients
COPD continues to be a cause of major morbidity for patients. Those patients who also have respiratory failure and obstructive sleep apnoea are at higher risk of exacerbations and death and have worse health related quality of…
- Trial name
- AVAPS-AE (NCT01601977)
- Testing
- AVAPS-AE, Usual care
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Patrick Murphy
Chronic Obstructive Pulmonary Disease (COPD)
Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD
The ultimate goal is to reduce unnecessary antibiotic prescriptions which drive the development of antibiotic resistance in the community.
- Trial name
- NCT01892488
- Testing
- Sultamicillin
- Where
- 32 sites in Germany
- Volunteers
- 295 people
- Sponsor
- Hannover Medical School
COPD Exacerbation
Platelet Activation and Reactivity in Acute Exacerbations of COPD
Chronic obstructive pulmonary disease (COPD) is known for development of severe cardiovascular co-morbidities. Systemic inflammation during acute exacerbations of COPD (AE-COPD) is thought to play a role in development of…
- Trial name
- NCT03017625
- Testing
- Blood is drawn
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Breathing-Related Sleep Disorder
A Pilot Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD
This is a multicenter, randomized, parallel-group, open label study of the efficacy of AVAPS-AE to prevent re-hospitalization in hospitalized patients with comorbid Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- STOP-BBACK (NCT02446769)
- Testing
- AVAPS-AE Non-invasive ventilation therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Philips Respironics
Severe Dyspnea, CAPD
BIOmarkers of Dyspnea IN Emergency Room
The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine…
- Conditions
- Severe Dyspnea, CAPD, AE COPD, Acute Heart Failure
- Trial name
- BIODINER (NCT01227317)
- Testing
- Prognostic value of Biomarkers
- Where
- France
- Volunteers
- 444 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
COPD, AE COPD
Predicting Acute Exacerbations of COPD Using Wearable Devices and Remote Monitoring Technology With AI/ML Models
This study is aimed to collect real-time physiological data using two wearable devices (a biometric ring and a biometric wristband), daily lung mechanical measurements by a handheld oscillometer, and participant-reported symptoms…
- Trial name
- ePredictAECOPD (NCT06802003)
- Testing
- Biometric wearable and handheld devices
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine whether there is a statistical association between changes in sputum serial levels of two cytokines, interleukin (IL)-17 and IL-6, during the treatment course of a severe acute…
- Trial name
- NCT00281242
- Testing
- blood draw
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Michigan
COPD Exacerbation, Copd
nCD64 vs. Neutrophil/Lymphocyte Ratio for Predicting In-hospital Outcome in AE-COPD
Neutrophil CD64 versus Neutrophil/Lymphocyte ratio (NLR) as markers predicting in-hospital outcome in acute exacerbation of COPD
- Trial name
- NCT03146611
- Testing
- nCD64, Neutrophil/Lymphocyte Ratio
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Assiut University